Market Wire - Pharmaceuticals and Biotech

Alpharma Inc.: Alpharma Announces the Resubmission of a New Drug Application for EMBEDA(TM) Capsules - June 30, 2008

BRIDGEWATER, NJ (MARKET WIRE) Alpharma Inc. (NYSE: ALO), a global specialty pharmaceutical company, today announced that it has resubmitted its New Drug Application ("NDA") for EMBEDA(TM) (morphine sulfate extended-release with sequestered naltrexone hydrochloride) Capsules to the U.S. Food and Drug Administration (the "FDA"). On February 28, 2008, the Company announced the initial submission of an NDA for EMBEDA(TM) Capsules and on April 21, 2008 announced the withdrawal of that NDA due to...
http://www2.marketwire.com/mw/release_html_b1?release_id=411880&tsource=3

BASi (Bioanalytical Systems, Inc.): BASi Announces Sale of Baltimore Clinical Pharmacology Research Unit - June 30, 2008

WEST LAFAYETTE, IN (MARKET WIRE) Bioanalytical Systems, Inc. (NASDAQ: BASI) announced today that it has sold its Baltimore Clinical Pharmacology Research Unit (the "CPRU") to a subsidiary of Algorithme Pharma Holdings, Inc. ("Algorithme"). As a result of this sale, BASi will exit the Phase I first-in-human clinical study market.
http://www2.marketwire.com/mw/release_html_b1?release_id=411911&tsource=3

VIVALIS: VIVALIS: FILING OF THE EB66(R) CELL LINE BMF WITH THE AMERICAN FDA - June 30, 2008

NANTES, FRANCE (MARKET WIRE) VIVALIS (NYSE Euronext: VLS) announces that on 27 June 2008 it filed the BMF (Biologics Master File), for registration of the EB66(R) cell line with the FDA (Food and Drug Administration), the American health regulation authority. The EB66(R) cell line results from the EBx(R) technology developed by VIVALIS from duck embryonic stem cells for use in the production of vaccines and therapeutic proteins.
http://www2.marketwire.com/mw/release_html_b1?release_id=411757&tsource=3

Institute for Pediatric Innovation: Institute for Pediatric Innovation Awarded Funding by University of Kansas to Analyze the Use of Extemporaneously - June 30, 2008

CAMBRIDGE, MA (MARKET WIRE) The Institute for Pediatric Innovation (IPI), Inc., a nonprofit focused on catalyzing the commercialization of products optimized for pediatric care, today announced that it has been awarded a $50,000 grant to analyze the use of extemporaneously prepared liquid formulations in children's hospitals. The study is being funded by the University of Kansas.
http://www2.marketwire.com/mw/release_html_b1?release_id=411708&tsource=3

AtheroGenics, Inc.: AtheroGenics Receives Notice of Non-Compliance With Listing Requirement for the NASDAQ Global Market - June 30, 2008

ATLANTA, GA (MARKET WIRE) AtheroGenics, Inc. (NASDAQ: AGIX), today reported that it received a Staff Determination Letter from the NASDAQ Listing Qualifications Department indicating that the Company has not regained compliance with the $1.00 per share bid price requirement for continued listing set forth in Marketplace Rule 4450(b)(4). As a result, shares of the Company's common stock are subject to delisting unless it requests a hearing before a NASDAQ Listing Qualifications Panel (the...
http://www2.marketwire.com/mw/release_html_b1?release_id=411698&tsource=3

Insera Therapeutics Inc. : Insera Therapeutics Wins Award at LifeScienceFest 2008 - June 30, 2008

SACRAMENTO, CA (MARKET WIRE) LifeScienceFest 2008 is pleased to announce that Insera Therapeutics, a Sacramento-based early-stage medical device company, received the 'Runner-Up' award for 'Most Promising Company' at the recent Venture Capital Conference held in Davis, CA.
http://www2.marketwire.com/mw/release_html_b1?release_id=411396&tsource=3

Cytokinetics, Inc.: Cytokinetics Announces Clinical Data Regarding Ispinesib in Combination With Capecitabine - June 30, 2008

SOUTH SAN FRANCISCO, CA (MARKET WIRE) Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the results of a Phase Ib clinical trial designed to evaluate ispinesib in combination with capecitabine, an oral chemotherapy agent commonly used in the treatment of breast cancer. Ispinesib is a novel, small molecule inhibitor of kinesin spindle protein (KSP), a mitotic kinesin essential for proper cell division. Ispinesib, along with another KSP inhibitor, SB-743921 are chemically-distinct drug.
http://www2.marketwire.com/mw/release_html_b1?release_id=411604&tsource=3

Active Biotech: Number of shares and votes in Active Biotech - June 30, 2008

LUND, SWEDEN (MARKET WIRE) The number of shares and votes in Active Biotech has changed as a consequence of the recently completed rights issue.
http://www2.marketwire.com/mw/release_html_b1?release_id=411636&tsource=3

Myriad Genetics: Myriad Genetics Reports Results of U.S. Phase 3 Trial of Flurizan(TM) in Alzheimer's Disease - June 30, 2008

SALT LAKE CITY, UT (MARKET WIRE) Myriad Genetics, Inc. (NASDAQ: MYGN) today announced results of the Act-Earli-AD trial, an 18-month Phase 3 study of Flurizan (tarenflurbil) in patients with mild Alzheimer's disease. The study did not achieve statistical significance on either of its primary endpoints -- cognition and activities of daily living.
http://www2.marketwire.com/mw/release_html_b1?release_id=411603&tsource=3